MRNA phase III melanoma success supports broader cancer expansion
The company cites positive phase III melanoma data and says manufacturing is at commercial scale, enabling global trials across lung, bladder and renal cancers.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.